Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ACELYRIN Inc.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female, ≥18 and ≤75 years of age.
Proptosis defined in the study eye as ≥3 mm above normal.
Clinical Activity Score (CAS) ≥4 (using a 7-item scale) for the most severely affected eye
Onset of active TED symptoms prior to baseline
Must agree to use highly effective contraception as specified in the protocol
You may not be if
Pathology related to inflammatory bowel disease or irritable bowel syndrome.
Clinically significant pathology related to hearing or history of hearing impairment
Optic neuropathy
Corneal decompensation unresponsive to medical management.
Previous orbital irradiation (for any cause) or any previous surgical treatment for TED.
Subjects with diabetes or hemoglobin A1c \>6.0% at screening
Any steroid use (intravenous \[IV\] or oral) with a cumulative dose equivalent to \>3 g of methylprednisolone for the treatment of TED within the last year.
Previous steroid use (IV or oral) specifically for the treatment of TED not to exceed 1 g total dose in the 8 weeks prior to Screening.
Previous use of teprotumumab or any other IGF-1 receptor (IGF-1R) inhibitor.
Any previous treatment with a biologic drug for the treatment of TED (eg, rituximab and tocilizumab)
Any other immunosuppressive agent within 1 month of screening.
Cohort 4 only: Prior history of craniofacial surgery or medical conditions that could alter orbital or facial features.